Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

JAMA

Volumn 278, Issue 16, 1997, Pages 1333-1339

  Sisk, Jane E ^a   Moskowitz, Alan J ^a   Whang, William ^a   Lin, Jean D ^b   Fedson, David S ^c,g,h   McBean, A Marshall ^d   Plouffe, Joseph F ^e   Cetron, Martin S ^f   Butler, Jay C ^f  

^a New York State Psychiatric Institute   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c Pasteur Merieux MSD   (France)

^d UNIVERSITY OF MINNESOTA   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g Columbia University ^*  (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; BACTEREMIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 0030771746     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.16.1333     Document Type: Article

References (52)

1. Willems JS, Sanders CR, Riddiough MA, Bell JC. Cost-effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med. 1980;303:553-559.
2. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med. 1986;104:78-86.
3. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Respir Infect. 1993;8:285-293.
4. Fedson DS, Shapiro ED, LaForce FM, et al. Pneumococcal vaccine after 15 years of use: another view. Arch Intern Med. 1994;154:2531-2535.
5. Gaillit J, Zmirou D, Mallaret MR, et al. Essai clinique du vaccin antipneumococcique chez des personnes. Rev Epidemiol Sante Publique. 1985;33:437-444.
6. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994:517-564.
7. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;315:1318-1327.
8. Simberkoff MS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness. Semin Respir Infect. 1994;8:294-299.
9. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med. 1994; 154:373-377.
10. Bennett NM, Buffington J, LaForce FM. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health. 1992;82:1513-1516.
11. Breiman RF, Spika JF, Navarro VJ, et al. Pneumococcal bacteremia in Charleston County, South Carolina: a decade later. Arch Intern Med. 1990;150: 1401-1405.
12. Campbell JF, Donohue MA, Mochizuki RB, et al. Pneumococcal bacteremia in Hawaii: initial findings of a pneumococcal disease prevention project. Hawaii Med J. 1989;48:517-518.
13. Davidson M, Schraer CD, Parkinson AJ, et al. Invasive pneumococcal disease in an Alaskan native population. JAMA. 1989;261:715-719.
14. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333:481-486.
15. Istre GR, Tarpay M, Anderson M, Pryor A, Welch D, and the Pneumococcus Study Group. Invasive disease due to Streptococcus pneumoniae in an area with a high rate of relative penicillin resistance. J Infect Dis. 1987;156:732-735.
16. Plouffe JF, Breiman RF, Facklam RR, for the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA. 1996;275:194-198.
17. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA. 1993;270:1826-1831.
18. Fedson DS. Adult immunization: summary of a National Vaccine Advisory Committee report. JAMA. 1994;272:113-137.
19. Plouffe JF, Moore SK, Davis R, Facklam RR. Serotypes of Streptococcus pneumoniae blood culture isolates from adults in Franklin County, Ohio. J Clin Microbiol. 1994;32:1606-1607.
20. Forrester HC, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high risk population. Am J Med. 1987;83:425-430.
21. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med. 1995;155:2336-2340.
22. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;352:1453-1458.
23. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988;108:653-657.
24. Austrian R. Confronting drug-resistant pneumococci. Ann Intern Med. 1994;121:807-809.
25. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831-1835.
26. ACP Task Force on Adult Immunization and Infectious Disease Society of America. Guide for Adult Immunization. 3rd ed. Philadelphia, Pa: American College of Physicians; 1994:107-114.
27. Fedson DS. Clinical practice and public policy for influenza and pneumococcal vaccination in the elderly. Clin Geriatr Med. 1992;8:183-199.
28. McBean AM, Babish JD, Prihoda R. The utilization of pneumococcal polysaccharide vaccine among elderly Medicare beneficiaries, 1985 through 1988. Arch Intern Med. 1991;151:2009-2016.
29. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage levels among persons aged >65 years - United States, 1973-1993. MMWR Morb Mortal Wkly Rep. 1995; 44:506-515.
30. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(No. RR-8):1-24.
31. Chiang CL. Competing risks in mortality analysis. Ann Rev Public Health. 1991;12:281-307.
32. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
33. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
34. Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Manage Sci. 1983; 29:300-306.
35. Laschober MA, Olin GL. Health and Health Care of the Medicare Population: Data From the 1992 Current Beneficiary Survey. Rockvilie, Md: Westat Inc; 1996:44, 133, 136.
36. Doubilet P, Begg CB, Weinstein MC, Brain P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Dec Making. 1985;5:157-177.
37. Hillier FS, Lieberman GJ. Operations Research. 2nd ed. San Francisco, Calif: Holden-Day; 1974:620-650.
38. Centers for Disease Control. Update: pneumococcal polysaccharide vaccine usage - United States. MMWR Morb Mortal Wkly Rep. 1984;33: 273-281.
39. Erickson P, Wilson R, Shannon I. Years of healthy life. Stat Notes. 1995;7:1-14.
40. US Council of Economic Advisers. Economic Report of the President. Washington, DC: US Government Printing Office; 1997:365.
41. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994; 331:778-784.
42. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA. 1983;249:3189-3195.
43. Willems JS, Sanders CR. Cost-effectiveness and cost-benefit of vaccines. J Infect Dis. 1981;144:486-493.
44. US Congress, Office of Technology Assessment. The Costs and Effectiveness of Cervical Cancer Screening in Elderly Women. Washington, DC: US Government Printing Office; February 1990.
45. US Congress, Office of Technology Assessment. The Costs and Effectiveness of Colorectal Cancer Screening in the Elderly. Washington, DC: US Government Printing Office; September 1990.
46. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
47. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J. 1993;148: 927-929.
48. US Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, DC: US Dept of Health and Human Services; 1991.
49. Fedson DS, Harward MP, Reid RA, Kaiser DL. Hospital-based pneumococcal immunization: epidemiologic rationale from the Shenandoah Study. JAMA. 1990;264:1117-1122.
50. Williams WW, Hickson MA, Kane MA, Kendal AP, Spika JS, Hinman AR. Immunization policies and vaccine coverage among adults: the risk for missed opportunities. Ann Intern Med. 1988;108: 616-625.
51. Gyorkos TW, Tannenbaum TN, Abrahamowicz M, et al. Evaluation of the effectiveness of immunization delivery methods. Can J Public Health. 1994; 85(suppl 1):S14-S30.
52. Schoenbaum SC. Feedback of clinical performance information. HMO Pract. 1993;7:5-11.